

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number  
WO 2004/087745 A1

(51) International Patent Classification<sup>7</sup>: C07K 7/08,  
G01N 33/564

(21) International Application Number:  
PCT/SE2004/000526

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0300958-6 2 April 2003 (02.04.2003) SE

(71) Applicant (for all designated States except US): PHARMACIA DIAGNOSTICS AB [SE/SE]; Uppsala, 751 82 (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MAHLER, Michael [DE/DE]; Bonnerstrasse, 41468 Neuss 216 (DE).

(74) Agent: DR LUDWIG BRANN PATENTBYRÅ AB; P.O. Box 1344, S-751 43 Uppsala (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/087745 A1

(54) Title: ANALYTICAL METHOD AND KIT THEREOF

(57) Abstract: The present invention relates to a peptide comprising a symmetrical dimethylated arginine, and constitute an immuno-logic determinant of antibodies present in sera from patients with systemic lupus erythematosus (SLE), and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptide for diagnosis of SLE and the differentiation between SLE and MCTD.

1/peaks

1

JC20 Rec'd PCT/PTO 30 SEP 2005

## ANALYTICAL METHOD AND KIT THEREOF

**Field of the invention**

The present invention relates to a peptide comprising a symmetrical dimethylated arginine, 5 and constitute an immunologic determinant of antibodies present in sera from patients with systemic lupus erythematosus (SLE), and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptide for diagnosis of SLE and the differentiation of SLE and mixed connective tissue disease (MCTD).

10

**Background of the invention**

Systemic rheumatic diseases are characterized by the occurrence of circulating autoantibodies to defined intracellular targets (reviewed in von Mühlen and Tan, 1995). Among the earliest of those autoantibodies to be identified were the anti-Sm, which are 15 closely associated with systemic lupus erythrematosus (SLE) (Tan and Kunkel 1966). Thus, anti-Sm antibodies have been included as one of the American College of Rheumatology classification criteria for this disease (Tan et al., 1982). Apart from autoantibodies targeting the Sm-complex anti-DNA, anti-PCNA, anti-U1-RNP, anti-nucleosome, anti-histone, anti-Ro/SS-A, anti-La/SS-B, anti-ribosomal RNP and anti- 20 phospholipid antibodies are frequently found in patients suffering from SLE (von Mühlen and Tan 1995).

In average anti-Sm reactivity is found in 5-30% of patients with SLE, although the specific frequency will vary depending on the detection system and the ethnicity of the SLE population (Abuaf et al., 1990; Jaekel et al., 2001). The Sm-antigen is part of the 25 spliceosomal complex that catalyzes the splicing of nuclear pre-mRNA (Seraphin, 1995; Lerner et al., 1980). The complex itself comprises at least nine different polypeptides with molecular weights ranging from 9 – 29.5 kDa [B (B1, 28 kDa), B' (B2, 29 kDa), N (B3, 29.5 kDa), D1 (16 kDa), D2 (16.5 kDa), D3 (18 kDa), E (12 kDa), F (11 kDa) and G (9 kDa)] (Hoch, 1994). All of those core proteins can serve as targets of the anti-Sm immune 30 response, most frequently the B and D polypeptides, which are therefore considered the

major antigens (Hoch, 1994; Brahms et al., 1997; Ou et al., 1997). However, SmBB' and U1 specific RNPs which are frequently the target of autoantibodies in patients with MCTD share crossreactive epitopes, consequently SmD is regarded as the most specific Sm-antigen (van Venrooij et al., 1991; Hoch et al., 1999). Within the SmD family the 5 SmD1/D3 pattern is at least four times more common than SmD1/D2/D3 recognition with a pronounced immunoreactivity to SmD1 (Hoch et al., 1999). In epitope-mapping studies, several linear and conformational epitopes have been mapped on the SmB- and D- proteins (Rokeach et al., 1992; Hirakata et al., 1993). On SmD1 and BB' the major reactivity was predominantly found in the C-terminal extensions (Rokeach et al., 1992; Hirakata et al., 10 1993; Rokeach and Hoch, 1992). The epitope PPPGMRPP that occurs three times within the C-terminal extensions of SmBB' was shown to crossreact with other prolin rich structures of spliceosomal autoantigens such as the U1 specific antigens and of retroviral proteins such as p24 gag of HIV-1 (De Keyser et al., 1992). Follow-up studies and immunization experiments revealed that this motif is consistently the earliest detectable 15 SmBB' epitope acting as starting point of epitope-spreading events within the BB' molecule and to the SmD- polypeptides (Arbuckle, 1999; Greidinger and Hoffman, 2001). A recent study identified five linear epitopes on SmD2 and four on SmD3 distributed on the entire molecules (McClain et al., 2002). All of these epitopes share basic properties and are exposed on the surface of the protein rendering them antigenic (McClain et al., 2002). 20 One of the described B-cell epitopes on SmD3 (epitope 4; aa 104-126) displayed close homology to an antigenic region from the SmD1 protein finally leading to crossreactivity (McClain et al., 2002). For diagnostic purposes a synthetic peptide corresponding to the C-terminal extension of SmD1 was used to develop an ELISA system with diagnostic sensitivities and specificities ranging from 36-70% and from 91.7% and 97.2%, 25 respectively (Riemekasten et al., 1998; Jaekel et al., 2001). Recently, it has been shown, that the polypeptides D1, D3 and BB' contain symmetrical dimethylarginine (sDMA) constituting a major autoepitope within the C-terminus of SmD1 (Brahms et al., 2000; Brahms et al., 2001). In one of these studies a synthetic peptide of SmD1 (aa 95-119) containing sDMA demonstrated significant increased immunoreactivity compared to the

non-modified peptide reflecting a conflict to previous data (Riemekasten et al., 1998; Brahms et al., 2000).

In WO 99/11667 a method is described for producing peptides containing methylated 5 arginines and that constitute immunogenic determinants of antibodies present in sera from patients with SLE or Epstein-Barr virus (EBV) and wherein the methylation is a prerequisite for reacting with said antibodies. However, these peptides are generally described and no connection between peptide sequence and ability to diagnose autoimmune disease has been disclosed.

10

#### Summary of the invention

We have now found that our claimed peptide comprising a symmetrical dimethylated arginine at a defined position is essential for the diagnosis of SLE, and it has surprisingly been shown that this peptide can be used in a highly specific and reliable diagnostic 15 immunoassay for selection of SLE patients and for the differentiation between SLE and MCTD. Multimers of the peptide can also be used for the same purposes.

A kit comprising the claimed peptide can be used for diagnosis of SLE as well as for differentiation between SLE and MCTD. The advantage of the claimed invention is that it does not pick up false positive samples from the group of MCTD samples.

20 It is an object of the present invention to provide an analytical method for detection of anti-Sm antibodies.

The present inventor has surprisingly found that symmetrical dimethylation of a certain arginine residue within the SmD3 sequence is crucial for its antigenicity.


25 Therefore, in one aspect, the present invention provides a peptide (S33) containing 15-16 amino acids, comprising symmetrical dimethylated arginine (sDMA), that is able to react with antibodies and with said dimethylation being crucial for the reaction between said peptide and said antibodies and wherein said antibodies are present in sera from patients with systemic lupus erythematosus (SLE).

In a second aspect the S33 peptide comprises the amino acid sequence

30 AARG sDMA GRGMGRGNIF

In a third aspect the symmetric dimethylated arginine has the position 112 in the polypeptide sequence of SmD3.

In a fourth aspect the S33 peptide comprises a symmetric dimethylated arginine with the structure



In a fifth aspect the invention is a method for use of the S33 peptide for in vitro diagnosis of SLE

10 In a sixth aspect the invention is a method for use of the S33 peptide for differentiation of SLE and mixed connective tissue disease (MCTD).

In a seventh aspect the invention is a kit for use of the S33 peptide for in vitro monitoring of the disease activity in dsDNA negative SLE patients, wherein the disease activity is defined as a correlation between the antibody titer and to the new mimotope peptide and the disease activity.

15 In an eight aspect the invention is a method to follow the antibody titer by repeated testing in order to monitor the effect of treatment or the disease activity

In a ninth aspect the invention is a multimer peptide comprising multiples of the S33 peptide

**Brief description of the drawings**

Figure 1. Epitope analysis of SmD1 and SmD3. C-terminal extensions of SmD1 (a) and SmD3 (b) were synthesized as peptide arrays (15mers; aa offset) and probed with patient sera. Immunoreactive peptide no. 77 was further tested as mimotope variants (c).

5

Figure 2. Assay performance characteristics of the new anti-S33 assay. Intra- and interassay variability a.), linearity (b.), and Receiver Operating Characteristic ROC-analysis including Positive Predictive Value (PPV), Negative Predictive Value (NPV) and efficiency at different cut-offs (c.).

10

Figure 3. A male SLE patient was clinically and serologically observed over a time period of 18 month.

**Detailed description of the invention**15 Example 1**Serum samples**

Sera (n=628) were collected from patients suffering from systemic lupus erythematosus (SLE; n=176), rheumatoid arthritis (RA, n=86), Sjögren syndrome (SS, n=24); mixed connective tissue disease (MCTD, n=26), scleroderma (SSc, n=26) and polymyositis / 20 dermatomyositis (PM/DM, n=13). All patients were classified according to the ACR-criteria for each disease (Tan et al., 1982; Arnett et al., 1988). To further assess the assay specificity, we analyzed a group of sera from patients with infection diseases (n=77) including hepatitis-C (HCV; n=30), cytomegalo (CMV; n=22) and Epstein-Barr Virus (EBV; n=25) as well as from 192 healthy blood donors. All sera were stored at -80°C until 25 use. For epitope-mapping a panel of five sera containing anti-Sm antibodies was used. As negative controls autoimmune sera with other antibody specificities than anti-Sm were selected.

**Serological characterization of randomly selected SLE patient sera.** All autoimmune patient sera were tested for autoantibodies to histones, dsDNA and the Sm-complex using 30 quantitative Varelisa® s (Pharmacia Diagnostics, Freiburg, Germany). SLE sera and

samples, which demonstrated unexpected results were also measured in the semi quantitative ANA-Split ELISA research Kit (Pharmacia, Freiburg, Germany). The latter assay contains the autoantigens U1-68kDa, U1-A, U1-C, SmBB', SmD, Ro-52, Ro-60 and La. All ELISAs were performed according to the instructions of use.

5

#### Example 2

##### **Epitope-mapping with immobilized oligopeptides**

The published sequences of SmD1, P13641, (Rokeach et al., 1988) and SmD3, P43331, (Lehmeier et al., 1994) were used to synthesize overlapping 15mer peptides with a 10 pipetting robot according to the protocol described by Gausepohl and Behn (2002). The C-terminal extensions of both polypeptides were synthesized with an offset of 2 amino acids (13 amino acids overlap). Each arginine containing peptide was synthesized as three variants, with natural arginine, with sDMA or with asymmetrical dimethylarginine (asDMA) at the respective positions. Later on, a highly reactive peptide of SmD3 was 15 synthesized with certain combinations of natural arginine and sDMA. Following completion of the peptide synthesis non-specific binding sites were blocked by over-night incubation of the membranes in blocking buffer (BB) at room temperature (RT). After one washing step membranes were incubated with serum samples at a dilution of 1:100 in BB for 2 h at RT. Unbound antibodies were removed by three washing steps. For detection 20 peroxidase conjugated goat-anti-human IgG antibody was diluted 1:5000 in BB and incubated for 75 min (RT). Superfluous secondary antibodies were removed by three washing steps. Finally, bound antibodies were visualized using the enhanced chemoluminescence (ECL) detection-system. Assay conditions were used under which negative sera showed no reactivity.

25

#### Example 3

##### **S33-peptide ELISA**

**Preparation of ELISA-plates.** The lyophilized S33 peptide was used to prepare a stock solution of 10 $\mu$ g/ $\mu$ l, which was stored in aliquots at -20°C until use. Binding of the 30 peptide to ELISA plates was carried out using 2.5 $\mu$ g/ml of the peptide in coating buffer in

a final volume of 120 $\mu$ l per well. The coating procedure was carried out at 15°C for 20h.

Unspecific binding sites were blocked with blocking solution. After discarding the blocking solution solid phases were dried at 37°C for 2h and sealed.

The assay was performed according to the general protocol of the Varelisa® system

5 (Pharmacia Diagnostics, Freiburg). Blood donors demonstrated a reactivity range of 0.4-11.5 U/ml resulting in a mean value of 2.2 U/ml and a SD of 1.2 U/ml. The cut-off was technically set to 13 U/ml after ROC-analysis. PPVs and NPVs were calculated at different cut-off values.

**Precision and reproducibility.** Measurements of imprecision (inter- and intra-assay

10 variability) were performed with 4 and 6 replicates, respectively. To assess precision of the anti-S33 peptide ELISA suitable anti-Sm sera, a low value sample (L); a medium value sample (M) and a high value sample (H) were assayed in five independent runs on one day (inter-assay), or in a single run (intra-assay). For within-run precision L, M and H were measured in six replicates on one solid phase. The precision data was calculated using

15 ANOVA analysis.

**Linearity.** The linearity was analyzed by testing dilutions (1:1; 2:3; 1:2; 1:4; 1:8; 1:16; 1:32) of the highest standard point (S6) and of the high value sample from the precision analysis (H). For each dilution point, a ratio of the measured reactivity to the expected value was calculated, and 1 was subtracted from this quotient.

20

**Example 4**

**Correlation study**

Randomly selected SLE sera (n=50) and various controls (n=100) were tested using the commercially available anti-Sm antibody tests from different suppliers (Sm test A – Sm

25 Test D) and the results were compared to the findings of the anti-S33 ELISA test.

**Example 5**

**Follow-up study of a SLE patient.**

A male SLE patient was clinically and serologically observed over a time period of 18

30 month (6 serum samples; see figure 3). The patient was tested for antibodies to the

RNP/Sm complex, to the Sm antigen, to the isolated U1-RNP complex, to histones, to dsDNA and to the S33 peptide using the respective test kits from Pharmacia Diagnostics.

### Results

5      **Epitope fine-mapping of the C-terminal extensions of SmD1 and D3.** To evaluate the effect of arginine-dimethylation on the antigenicity of SmD1 and SmD3 and to map relevant epitopes on both polypeptides a panel of anti-Sm sera was tested with peptide arrays (15mer, 2 offset) covering the C-terminal region of SmD1 (P13641) and SmD3 (P43331).

10     The results show that dimethylation of arginine residues affects the binding of anti-Sm antibodies to C-terminal SmD1- and D3 polypeptides, significantly (see figure 1). All anti-SmD sera (#36, #37, #31, #84, #Sm) demonstrated an increased binding to SmD1 peptides containing the symmetrical form of dimethylarginine (sDMA). Especially the peptides that consist of glycine and DMA repeats, exclusively showed a strong reactivity with the

15     antibodies (peptide no. 9, 10). Nevertheless, SmD1 polypeptides containing DMA represent a rather unspecific substrate for anti-Sm antibodies since they were also target of anti-centromere antibodies (ACA; #serum CEN (centromer)). Interestingly, those ACA bound also to peptides containing the asymmetrical form of DMA.

Binding experiments with peptides derived from SmD3 showed similar results. Only

20     SmD3 peptides containing sDMA reacted with anti-Sm antibodies confirming the importance of the symmetric methylation of arginine residues (see figure 1b). In contrast to SmD1, no control serum (e.g. CEN) demonstrated antibody binding to SmD3 derived peptides reflecting a high specificity. One particular peptide (no. 77, <sup>108</sup>AA<sub>sd</sub>RG<sub>sd</sub>RG<sub>sd</sub>RGMG<sub>sd</sub>RGNIF<sup>122</sup>) was strongly recognized by three out of five anti-

25     Sm sera. Using a mutational analysis in which arginine residues of <sup>108</sup>AARGRGRGMGRGNIF<sup>122</sup> were successively replaced by sDMA we were able to show that a mimotope peptide with a single dimethylated arginine residue at position 112 displayed immunoreactivity with all of the five anti-Sm sera (#36, #37, #31, #84, #Sm) but not with the controls (e.g. CEN; see figure 1c.). Thus, by introducing only one sDMA and

30     at a defined position (amino acid 112) of SmD3, it was possible to increase the sensitivity

of this peptide (<sup>108</sup>AARGsdRGRGMGRGNIF<sup>122</sup>; S33) without a loss in specificity. This candidate peptide was subsequently synthesized as soluble antigen and used as substrate in ELISA.

5    **Immunoserologic characterization of the SLE patient group.** To evaluate if our SLE patient cohort represents a representative SLE serum panel approximately 100 SLE samples were randomly selected and tested for U1-68kD, U1-A, U1-C, SmBB', SmD, Ro-52/SS-A, Ro-60/SS-A, La/SS-B, histone dsDNA and  $\beta$ 2-glycoprotein reactivity (Split ANA-Profil research assay, Pharmacia Diagnostics, Freiburg, Germany). The prevalence 10 of the different autoantibodies was found in a good agreement to previous studies (Jaekel et al., 2001). Thus, with regard to their autoantibody profiles, the SLE cohort seems to be a representative SLE population. Results of the measurements of the SLE panel are summarized in table 1.

15    Table 1.    Prevalence (%) of clinically relevant autoantibody specificities in patients suffering from SLE (n=101)

Autoantibodies to											$\beta$ 2-
U1-	U1-	U1-	SmBB	Sm	Ro-	Ro-	Histon	dsDN	Glycoprotei		
68	A	C	'	D	52	60	La	e	A	n	
15.	24.	25.			21.	47.	21.				
8	8	7	21.8	15.8	8	5	8	37.6	51	17	

#### Anti-S33 peptide ELISA

20    A 15 amino acid soluble peptide displaying highest sensitivity and specificity in the SPOT-assay (<sup>108</sup>AARGsdRGRGMGRGNIF<sup>122</sup>) was synthesized for technical reasons with an additional Cys at the C-terminus. This peptide was subsequently used to develop an ELISA system based on the general protocol of the Varelisa® tests (Pharmacia, Freiburg, Germany).

**Assay performance characteristic.** To evaluate the assay performance characteristics precision, reproducibility and linearity were analyzed. The intra- and interassay variability (CV%) of three samples were found ranging from 1.82 to 6.52% and from 2.27 to 7.42%, respectively. Dilution series of two samples demonstrated a linear range on five subsequent 5 dilutions (>20% deviation). For the cut-off definition a receiver operating characteristic (ROC)- analysis was performed with SLE and control sera. The assay performance characteristics of the new anti-S33-test including intra- and interassay variability (a.), linearity (b.), ROC-analysis, PPV, NPV and efficiency (c.) are summarized in figure 2 (a. – c.).

10 For the evaluation of the diagnostic relevance of the new test a technical cut-off of 13U/ml was used to combine high specificity with moderate sensitivity. Sera from 176 SLE patients, from 181 autoimmune patients diagnosed differently than SLE, from 77 patients with infection diseases and from 192 human normal donors were analyzed in the new ELISA system. 28 SLE patients (15.9%) were tested positive for anti-S33 antibodies 15 displaying a significantly increased reactivity of up to 952 U/ml with a mean value of 43 U/ml (SD = 160.2 U/ml). Patients from related disorders demonstrated a significant reduced reactivity in the new ELISA system (mean 3.36 U/ml). Only one patient of the RA group was assayed positive (24.6 U/ml). None of the remaining controls including patients suffering from SSc (n=26), PM/DM (n=13), MCTD (n=126) or infection diseases (n=77) 20 showed reactivity to the S33 peptide. The serum samples from patients with infectious diseases demonstrated a reduced reactivity (mean 0.67 U/ml; top value 3.3 U/ml), even when compared to the healthy donors (mean 2.21 U/ml; top value 11.5 U/ml). The top value of the infectious disease sera was found in the EBV group. Results are summarized in Table 2.

**Table 2. Results of ELISA using S33 with SLE and various control sera**

	No. (%) of anti-S33-positive sera	Mean value (U/ml)	Top value (U/ml)
<i>SLE (n=176)</i>	<b>28 (15.9)</b>	<b>43.0</b>	<b>1190.0</b>
<i>Rheumatic diseases (181)</i>			
<i>RA (86)</i>	<b>1 (0.6)</b>	<b>2.2</b>	<b>24.6</b>
<i>pSS (24)</i>	<b>1 (1.2)</b>	<b>1.6</b>	<b>24.6</b>
<i>MCTD (26)</i>	<b>0</b>	<b>1.9</b>	<b>3.9</b>
<i>SSc (26)</i>	<b>0</b>	<b>3.1</b>	<b>12.8</b>
<i>PM/DM (13)</i>	<b>0</b>	<b>2.4</b>	<b>4.3</b>
<i>Infectious diseases (77)</i>	<b>0</b>	<b>2.8</b>	<b>9.6</b>
<i>HCV (30)</i>	<b>0</b>	<b>0.67</b>	<b>3.3</b>
<i>CMV (22)</i>	<b>0</b>	<b>0.42</b>	<b>1.1</b>
<i>EBV (25)</i>	<b>0</b>	<b>0.8</b>	<b>3.2</b>
<i>Healthy individuals (192)</i>	<b>0</b>	<b>0.78</b>	<b>3.3</b>
		<b>2.21</b>	<b>11.5</b>

In summary, 15 samples of the SLE group (n=176) and only one serum of the controls  
 5 (n=449, 0.2%) was tested positive resulting in a diagnostic specificity of 99.8% and a sensitivity of 15.9%. PPV and NPV, as well as the diagnostic efficiency was calculated at 96.6%, 75.3% and 76.3%, respectively (see figure 2 c.). These data indicate that anti-S33 antibodies appear to be exclusively present in sera from SLE patients.

10 Apart from the anti-s33 peptide reactivity the false positive ra sample contains high titers of antibodies to the u1-rnps- 68kda (ratio 4.5), u1-c (ratio 9.4) and histones (133.8 u/ml) (see table 3). Anti-smbb' and anti-smd titers as determined by elisa were elevated when compared to the controls, but still below the cut-off values (see table 3).

**Table 3. Autoantibody-profile of the false positive RA patient in the new S33 peptide assay**

Seru m ID	Contr ol	U1- 68kD	U1	U1	SmBB'	SmD	Ro	Ro	La	histon	dsDNA
#	group	*	A*	C*			52	60		[U/ml]	[U/ml]
							*	*			
R15	Ra	4.5	0.6	9.2	0.8	0.8	0.2	0.7	0.5	133.8	15.6

\*semiquantitative Assay (ANA-Split); cut-off >1.4

<sup>1</sup>cut-off (30U/ml)

5       $^2$ cut-off (55U/ml)

**Correlation to other autoantibodies.** With regard to possible existing correlations between anti-S33 antibodies and other autoantibody species, a statistic evaluation was performed using the SLE panel of approximately 100 randomly selected sera. Significant correlations were to U1-68kDa ( $p = 0.0335$ ), U1-A ( $p < 0.0001$ ), U1-C ( $p < 0.0001$ ) SmBB' ( $p < 0.0001$ ), SmD ( $p < 0.0001$ ), dsDNA ( $p < 0.0001$ ) and histone ( $p < 0.0001$ ), but not to Ro-52 ( $p = 0.2192$ ), Ro-60 ( $p = 0.2212$ ) and La ( $p = 0.8785$ ) (see table 4).

**Table 4. Association between anti-S33 positivity and other Aab species in SLE**

Pearson correlation; \* Statistically significant

Looking at the reactivity towards the Sm-complex, five samples of the randomly selected  
5 SLE patients (n=101) reacted with the purified SmD antigen , but not with the S33 peptide. The remaining 11 SmD positive sera (68.8%) were also tested positive in the new anti-S33 peptide ELISA. Interestingly, among the anti-S33 positive samples, 4 patients (#89, #92, #20627, #9811) were found, all anti-SmD negative showing anti-S33 peptide reactivities of 15.4, 21.3, 41.3 and 13.9 units, respectively.

10

To evaluate correlations to commercially available anti-Sm antibody tests from different suppliers 50 randomly selected SLE sera from the SLE patient group and 100 controls were tested using the anti-Sm antibody tests from different suppliers. 6 out of 50 SLE sera (12%) and none of the controls (0%) were positive in the anti-S33 antibody test resulting in  
15 a sensitivity of 12% and a specificity of 100%. In contrast the anti-Sm assay from different suppliers Sm test A, B and C accessed only 5 SLE samples (10%) and between 6 (Sm test A, C) and 12 (Sm test D) patients from the control group. The majority of false positive results were found within the group of MCTD patients (see Table 5).

Table 5 Reactivity of control sera, mainly MCTD in the tests from different suppliers

No.	ID	Diagnosis	Immunoassays				
			Varelisa(R)	Sm Test A	Sm Test B	Sm Test C	Sm Test D
			U/ml	RE	Units	Ratio	Ratio
® S33							
			13 <sup>#</sup>	20 <sup>#</sup>	40 <sup>#</sup>	1 <sup>#</sup>	1 <sup>#</sup>
105	25516	MCTD	3.0	87.9	118.8	1.1	4.8
107	25518	MCTD	1.0	14.4	37.5	0.3	1.4
108	25519	MCTD	0.0	6.7	52.0	0.9	2.7
110	25521	MCTD	0.5	87.4	111.7	1.5	4.2
112	25523	MCTD	0.0	21.6	34.1	0.6	0.3
121	25532	MCTD	2.6	7.4	26.9	0.3	3.5
123	25534	MCTD	1.1	10.5	41.7	0.6	2.3
126	25537	MCTD	3.2	7.2	41.4	0.3	0.3
128	25539	MCTD	0.7	4.2	67.1	0.5	3.7
129	25540	MCTD	4.1	118.5	132.4	2.4	3.1
132	25543	MCTD	2.4	12.8	42.7	0.3	2.3
133	25544	MCTD;SL					5.4
		E	9.9	136.0	153.7	7.9	
137	25448	SSc	2.2	72.2	105.3	1.2	2.8
145	25456	MCTD	1,1	8,4	30,9	0.3	1.5

5 #suggested cut-off values

Follow-up study of a SLE patient. A male SLE patient was clinically and serologically observed over a time period of 18 month (6 serum samples; see figure 3). At the beginning of the follow-up study the patient displayed a strong immunoresponse towards the RNP/Sm complex (ratio of 18), to the Sm antigen (ratio of 6), to the new Sm antigen (337.5 U/ml) and a moderate response to the isolated U1-RNP complex (ratio of 2) as well as to histones (59.5 U/ml). No reactivity to dsDNA could be found (19.1U/ml; cut-off 55U/ml). At that time point the medical record reported an inactive phase of disease. Later on the antibody titer towards the new Sm antigen significantly increased reaching its peak in the third serum sample withdrawn in August 1999. In contrast a decreasing anti-RNP/Sm titer could be observed between the second and the fourth blood sampling followed by another strong increase in the fifth sample. At that time point the titer against

the new Sm antigen (S33) was lower than before and the disease status was reported as inactive according to the medical record. No significant alterations could be observed in the anti-dsDNA and anti-histone titer during the observation time of the patient.

5 In the presented examples the anti-Sm immune response have been analyzed towards the Sm antigens D1 and D3, which are considered to be the SLE specific polypeptides (van Venrooij et al., 1991; Hoch et al., 1999). Using immobilized peptides it has been shown that symmetric dimethylation of arginine residues plays an important role in the formation of the major B-cell epitopes on both autoantigens. This observation was found in a good  
10 agreement to the result of Brahms et al. (2000) and thus contradictory to the findings of Riemekasten and colleagues (1998). Interestingly and in addition to previous investigations, it was found that with peptides as previously described the specificity of SmD3 peptides was higher than of those derived from SmD1.

McClain and colleagues (2002) described four antigenic regions on SmD3 of which  
15 antigenic region 4 covers the area 104-126. In this invention peptides synthesized on pins were subjected to analysis but without using the modified form of arginine. In the present invention reactivity within this region was only found in case natural arginine was replaced by sDMA. These contradictory results might be explained by the use of different sera, methodology and / or by the varying peptide length. Three out of five sera specifically  
20 recognized the peptide <sup>108</sup>AAsdRGsdRGsdRGMGsdRGNIF<sup>122</sup> of this example.

Interestingly, the dimethylation of only one arginine and at a defined position (aa 112) could further increase the sensitivity of this particular mimotope peptide without a loss in specificity. Based on this data a candidate peptide was used  
(<sup>108</sup>AARGsdRGRGMGRGNIF<sup>122</sup>) to develop an ELISA system. The new anti-Sm assay  
25 (anti-S33) demonstrated a sensitivity of 14.9% and a specificity of 99.7% for lupus resulting in a high positive (PPV; 93.7%) and negative predictive value (NPV; 80.2%) and thus a high diagnostic efficiency (80.7%). Therefore this test offers new opportunities for the diagnosis of systemic lupus erythematosus, especially for the differentiation between SLE and MCTD as revealed by the correlation study.

Looking at the biochemical properties of the identified Sm-epitopes reveals that the pI can be regarded as predictor of antigenicity on the Sm-complex. On U1-RNP-A, SmB' and D1, the average pI of antigenic regions was 10.4 (nonantigenic 6.0) and on SmD2 and D3 more than pIs 9.0 (McClain et al., 2002). These inventive findings fit well to the high pI of the 5 S33 peptide (>12.88). Whether the basic character simply increases the probability of surface exposure of these regions and thus the accessibility to antibodies has to be further investigated.

**EBV, EBNA and anti-SmD antibodies.** Epitope-mapping studies on SmD1 have 10 identified an epitope-motif (aa 95-119) that cross-reacts with a homologue sequence 35-58 of the Epstein-Barr virus nuclear antigen 1 (EBNA-1) (Sabbatini et al., 1993; Sabbatini et al., 1993; Marchini et al., 1994). A more recent study has shown that this epitope also cross-reacts with a homologue region of SmD3 containing glycine arginine repeats (RGRGRGMGR) (McClain et al., 2002). Moreover it became evident that GPRR (aa 114- 15 119 on SmD1) represents a common cross-reactive autoepitope motif, which is present not only on EBNA-1, but also on a variety of autoantigens including CENP-A, B, C, SmBB', SmD1 and Ro-52, to term only a few (Mahler et al., 2001). Thus patients suffering from infectious mononucleosis or SLE related disorders might be tested false positive in ELISAs using the C-terminal extensions of SmD1 or SmD3. Furthermore, several studies 20 have suggested an influence of EBV on the development of Lupus-like conditions (James et al., 1997). Therefore, it is considered that the use of EBV positive sera as controls is an important finding towards a highly specific and reliable anti-SmD immunoassay. Among the 25 EBV disease controls presented, no false positive sample was found confirming the suggested high specificity of the anti-S33-abs assay. Unfortunately, Riemeckasten and 25 colleagues (1998) did not include this patient group in the evaluation of their test.

**Correlations to other autoantibody species.** Overlapping reactivity between DNA and Sm antigens has been reported in several publications (Bloom et al., 1993; Reichlin et al., 1994; Zhang et al., 1995). While in these studies full-length SmD was used, in present 30 invention, there was also a correlation of the anti-dsDNA and anti-S33 reactivity ( $p <$

0.0001). Apart from DNA the present invention also shows a positive correlation of anti-S33 to U1-68 ( $p < 0.0001$ ), U1-A ( $p < 0.0001$ ), U1-C ( $p < 0.0001$ ), SmBB' ( $p < 0.0001$ ), Sm ( $p < 0.0001$ ) and SmD ( $p < 0.0001$ ), but not to histones ( $p = 0.0259$ ), La ( $p = 0.8747$ ), Ro-52 ( $p = 0.4034$ ) and Ro-60 ( $p = 0.0143$ ). Whether the observed associations are caused 5 by cross-reactivity or by different autoantibody species that often occur simultaneously, remains unclear. Further studies have to be addressed to shed more light on this issue.

**Riemekasten vs Brahms.** The obvious conflict between the results of Riemekasten et al. and Brahms et al. might be explained by the existence of different epitopes on the C-terminal extensions of SmD1. The peptide aa 83-119 (Riemekasten et al., 1998) may form a conformational epitope, whereas the shorter peptides used in the second study contain linear, sDMA dependent binding sites (Brahms et al., 2000). Furthermore, the reduced reactivity against the full-length SmD1 (Riemekasten et al., 1998), compared to SmD1<sub>83-119</sub> peptide, suggests that this peptide epitope represents a cryptic structure. This observation 10 raises the question, which epitopes are "seen" *in vivo* and which ones play the central role in the pathogenesis of SLE. In a recent study it became evident, that the injection of 15 SmD1<sub>83-119</sub> fused to a carrier protein is able to accelerate the pathogenic process of Lupus-prone mice (Riemekasten et al., 2001).

20 **"Rhupus"-Syndrom.** Rheumatoid Arthritis (RA) and systemic lupus erythremtosus (SLE) are related disorders with an autoimmune etiology. Both diseases are accompanied by the occurrence of self-reactive antibodies to defined structures. Several studies have reported overlap syndromes between RA and Lupus, which were therefore sometimes called the "Rhupus"-Syndrom (Miyachi and Tan, 1979; Panush et al., 1988; Brand et al., 1992). In 25 the presented examples one patient was found within the RA group who demonstrated anti-S33 reactivity (24.6 U/ml). Whether this result reflects a false positive testing or whether autoantibodies to the S33 peptide represent a precursor of lupus-like conditions remains unclear and has to be investigated.

**References**

Abuaf N, Johonet C, Chretien P, Absalon BI, Homberg JC, Buri JF. Detection of 5 autoantibodies to Sm antigen in systemic lupus erythematosus by immunodiffusion, ELISA and immunoblotting: variability of incidence related to assays and ethnic origin of patients. *Eur J Clin Invest.* 1990 Aug;20(4):354-9.

Arbuckle MR, Reichlin M, Harley JB, James JA. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. *Scand J Immunol.* 1999 10 Nov;50(5):447-55.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988 Mar;31(3):315-24.

Arnett FC, Hamilton RG, Roebber MG, Harley JB, Reichlin M. Increased frequencies 15 of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. *J Rheumatol.* 1988 Dec;15(12):1773-6

Bloom DD, Davignon JL, Cohen PL, Eisenberg RA, Clarke SH. Overlap of the anti-Sm and anti-DNA responses of MRL/Mp-lpr/lpr mice. *J Immunol.* 1993 Feb 15;150(4):1579- 20 90.

Brahms H, Raker VA, van Venrooij WJ, Luhrmann R. A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E-F-G complex but not in their denatured states. *Arthritis Rheum.* 1997 Apr;40(4):672-82.

Brahms, H., Raymackers, J., Union, A., de Keyser, F., Meheus, L., Lührmann, R., 25 The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. *J. Biol. Chem.* 275, 17122-17129, 2000.

Brahms H, Meheus L, de Brabandere V, Fischer U, Luhrmann R. Symmetrical 30 dimethylation of arginine residues in spliceosomal Sm protein B/B' and the Sm-like protein LSm4, and their interaction with the SMN protein. *RNA.* 2001 Nov;7(11):1531-42.

**De Keyser F, Hoch SO, Takei M, Dang H, De Keyser H, Rokeach LA, Talal N.** Cross-reactivity of the B/B' subunit of the Sm ribonucleoprotein autoantigen with proline-rich polypeptides. *Clin Immunol Immunopathol* 1992 Mar;62(3):285-90

**Gausepohl, H., Behn, C.** Automated Synthesis of Solid-Phase Bound Peptides. *In*  
5 "Peptide Arrays on Membrane supports, Synthesis and Applications" (J. Koch and M. Mahler, Eds), pp.55-68, Springer Verlag, Heidelberg, New York, 2002.

**Greidinger EL, Hoffman RW.** The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'/B proteins as predominant U1 RNP immunogens. *Arthritis Rheum.* 2001  
10 Feb;44(2):368-75.

**Hirakata M, Craft J, Hardin JA.** Autoantigenic epitopes of the B and D polypeptides of the U1 snRNP. Analysis of domains recognized by the Y12 monoclonal anti-Sm antibody and by patient sera. *J Immunol.* 1993 Apr 15;150(8 Pt 1):3592-601.

**Hoch SO, Eisenberg RA, Sharp GC.** Diverse antibody recognition patterns of the  
15 multiple Sm-D antigen polypeptides. *Clin Immunol.* 1999 Aug;92(2):203-8.

**Hoch, S. O.,** The Sm antigens. In „Manual of biological Markers of disease“ (R. N. Maini and W.J. van Venrooij, Eds.), pp. B2.4/1-29, Kluwer Academic, Dordrecht, The Netherlands, 1994.

**Jackel HP, Klopsch T, Benkenstein B, Grobe N, Baldauf A, Schoessler W, Werle E.**  
20 Reactivities to the Sm Autoantigenic Complex and the Synthetic SmD1-aa83-119 Peptide in Systemic Lupus Erythematosus and other Autoimmune Diseases. *J Autoimmun.* 2001 Dec;17(4):347-54.

**James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB.** An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible  
25 etiology for systemic lupus erythematosus. *J Clin Invest.* 1997 Dec 15;100(12):3019-26.

**Lehmeier T, Raker V, Hermann H, Luhrmann R.** CDNA cloning of the Sm proteins D2 and D3 from human small nuclear ribonucleoproteins: Evidence for a direct D1-D2 interaction. *Proc. Natl. Acad. Sci.* 1994 Dec; 91:12317-12321

**Lerner MR, Boyle JA, Mount SM, Wolin SL, Steitz JA.** Are snRNPs involved in  
30 splicing? *Nature.* 1980 Jan 10; 283(5743):220-4.

**Mahler M, Mierau R, Schlumberger W, Bluthner M.** A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. *J Mol Med* 79, 722-31

5 **Marchini B, Dolcher MP, Sabbatini A, Klein G, Migliorini P.** Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases. *J Autoimmun.* 1994 Apr;7(2):179-91.

**McClain MT, Ramsland PA, Kaufman KM, James JA.** Anti-sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal 10 autoantigens. *J Immunol.* 2002 Feb 15;168(4):2054-62.

**Panush RS, Edwards NL, Longley S, Webster E.** 'Rhupus' syndrome. *Arch Intern Med.* 1988 Jul;148(7):1633-6.

**Reichlin M, Martin A, Taylor-Albert E, Tsuzaka K, Zhang W, Reichlin MW, Koren E, Ebling FM, Tsao B, Hahn BH.** Lupus autoantibodies to native DNA cross-react with the A and D SmRNP polypeptides. *J Clin Invest.* 1994 Jan;93(1):443-9.

15 **Riemekasten G, Marell J, Trebeljahr G, Klein R, Hausdorf G, Haupl T, Schneider-Mergener J, Burmester GR, Hiepe F.** A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. *J Clin Invest.* 1998 Aug 15;102(4):754-63.

20 **Riemekasten G, Kawald A, Weiss C, Meine A, Marell J, Klein R, Hocher B, Meisel C, Hausdorf G, Manz R, Kamradt T, Burmester GR, Hiepe F.** Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide. *Arthritis Rheum.* 2001 Oct;44(10):2435-45.

**Roeach LA, Haselby JA, Hoch SO.** Molecular cloning of a cDNA encoding the human 25 Sm-D autoantigen. *Proc. Natl. Acad. Sci.* 1988 Jul; 85(13): 4832-6

**Roeach LA, Jannatipour M, Haselby JA, Hoch SO.** Mapping of the immunoreactive domains of a small nuclear ribonucleoprotein-associated Sm-D autoantigen. *Clin Immunol Immunopathol.* 1992 Dec;65(3):315-24.

**Roeach LA, Hoch SO.** B-cell epitopes of Sm autoantigens. *Mol Biol Rep.* 1992 30 Jun;16(3):165-74. Review.

**Sabbatini A, Bombardieri S, Migliorini P.** Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. *Eur J Immunol* 1993 May;23(5):1146-52

5 **Sabbatini A, Dolcher MP, Marchini B, Bombardieri S, Migliorini P.** Mapping of epitopes on the SmD molecule: the use of multiple antigen peptides to measure autoantibodies in systemic lupus erythematosus. *J Rheumatol*. 1993 Oct;20(10):1679-83.

**Seraphin B.** Sm and Sm-like proteins belong to a large family: identification of proteins of the U6 as well as the U1, U2, U4 and U5 snRNPs. *EMBO J*. 1995 May 1;14(9):2089-98.

10 **Tan EM, Kunkel HG.** Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. *J Immunol*. 1966 Mar;96(3):464-71.

**Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ.** The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1982 Nov;25(11):1271-7.

15 **von Muhlen CA, Tan EM.** Autoantibodies in the diagnosis of systemic rheumatic diseases. *Semin Arthritis Rheum*. 1995 Apr;24(5):323-58. Review.


**Ou Y, Sun D, Sharp GC, Hoch SO.** Screening of SLE sera using purified recombinant Sm-D1 protein from a baculovirus expression system. *Clin Immunol Immunopathol*. 1997 Jun;83(3):310-7.

20 **Zhang W, Reichlin M.** IgM anti-A and D SnRNP proteins and IgM anti-dsDNA are closely associated in SLE sera. *Clin Immunol Immunopathol*. 1995 Jan;74(1):70-6.

Preliminary criteria for the classification of systemic sclerosis (scleroderma).  
Subcommittee for scleroderma criteria of the American Rheumatism Association  
25 Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum*. 1980 May;23(5):581-90.

**Claims**

- 1) A peptide (S33) containing 15-16 amino acids, comprising symmetrical dimethylated arginine (sDMA), that is able to react with antibodies which are present in sera from patients with systemic lupus erythematosus (SLE) .  
5
- 2) The S33 peptide according to claim 1 comprising the amino acid sequence AARG sdRGRGMGRGNIF.
- 3) A peptide according to claims 1 and 2 where the dimethylated arginine has the position 112 in the polypeptide sequence of SmD3.  
10
- 4) The peptide according to claims 1 or 2 or 3, wherein the structure of the symmetric dimethylated arginine is



15

- 5) Use of a peptide (S33) containing 15-16 amino acids, comprising symmetrical dimethylated arginine (sDMA), that is able to react with antibodies that are present in sera from patients with systemic lupus erythematosus (SLE) for diagnosis of SLE patients.

20

6) Use of a peptide (S33) according to claim 5 for differential diagnosis to distinguish between SLE patients and patients with mixed connective tissue disease (MCTD).

7) Use according to claim 5, wherein the diagnosis is an in vitro diagnosis of SLE .

5

8) Use according to claim 5, wherein said peptide is used for in vitro monitoring of the disease activity of dsDNA negative SLE patients.

9) Use according to claim 5, wherein said peptide is used for differentiation between

10 SLE and MCTD.

10) Use according to any of claims 5 to 9, wherein said peptide comprises the amino acid sequence


AARG sdRGRGMGRGNIF

15

11) Use of a peptide according to any of claims 5 to 10 where the dimethylated arginine has the position 112 in the polypeptide sequence of SmD3.

12) Use of a multimer peptide comprising the peptide of claim 1.

13) Use according to any of claims 5 to 12, wherein the structure of the symmetric dimethylated arginine is



14) A kit for detection of antibodies, comprising a peptide (S33) of 15-16 amino acids  
5 of which one is a symmetrical dimethylated arginine (sDMA), and is able to react with  
said antibodies that are present in sera from patients with systemic lupus erythematosus  
(SLE).

15) A kit according to claim 14, wherein said peptide is used for in vitro diagnosis of  
10 SLE.


16) A kit according to claim 14, wherein, wherein said peptide is used for differential  
diagnosis to distinguish between SLE and mixed connective tissue disease (MCTD).

15 17) A kit according to any of claims 14 to 16, wherein said peptide comprises the  
amino acid sequence

AARG sdRGRGMGRGNIF.

18) A kit for use of a peptide according to any of claims 14 to 17 where the  
20 dimethylated arginine has the position 112 in the polypeptide sequence of SmD3.

19) A kit according to any of claims 14 to 18, wherein the structure of the symmetric dimethylated arginine is




5 20) A method for monitoring a disease activity comprising repeated testing to follow the antibody titer in order to monitor the effect of treatment or the disease activity.

10

15

## SMD1

Fig. 1a




R = arginine

S = symmetrical dimethylarginine

A = asymmetrical dimethylarginine

Fig. 1b



R = arginine


S = symmetrical dimethylarginine

A = asymmetrical dimethylarginine

3/7

Fig.

1. c.)



4/7

Fig. 2a

## Antibody concentration

Low    Medium    High

## Intra-assay

Mean [U/ml]	7.1	36.3	83.8
CV (%)	1.82	3.79	6.52

## Inter-assay

Mean [U/ml]	7.48	36.54	91
CV (%)	3.97	7.42	2.27

5/7






Fig. 2b

6/7

Fig. 2c



7/7




Fig. 3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000526

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 7/08, G01N 33/564

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K, G01N, A61K, A61P, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI DATA, EPO INTERNAL, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9911667 A1 (INNOGENETICS N.V.), 11 March 1999 (11.03.1999), page 12, line 28 - page 13, line 3, claims --	1,4-6,9-11, 14
A	The Journal of Biological Chemistry, vol. 275, no. 22, Hero Brahms et al: "The C-terminal RG Dipeptide Repeats of the Spliceosomal Sm Proteins D1 and D3 Contain Symmetrical Dimethylarginines, which Form a Major B-cell Epitope for Anti-Sm Autoantibodies", figure 1, page 17124, column 2, line 7, page 17125, column 1, line 2, discussion, pages 17122 - 17129 --	1-14

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier application or patent but published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search

9 June 2004

Date of mailing of the international search report

24-06-2004

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. + 46 8 666 02 86

Authorized officer

Lars Wallentin/ELY  
Telephone No. + 46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/SE 2004/000526

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: **5-11 and 13**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**See extra sheet**
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No. PCT/SE 2004/000526
---

Claims 5-11 and 13 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000526

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>The American Association of Immunologists, 2002,        Micah T. McClain, "Anti-Sm Autoantibodies in        Systemic Lupus Target Highly Basic Surface        Structures of Complexed Spliceosomal Autoantigens",        sammandrag, pages 2054 - 2062</p> <p>--</p>	1-14
X	<p>National Library of Medicine (NLM), file Medline,        Medline accession no. NLM11317283, Tagawa Y. et al:        "Parameters for monitoring treatment effects in        CIDP with anti-MAG/SGPG IgM antibody";        &amp; Muscle &amp; nerve, volume 24, no. 5,        May 2001, page 701-704, abstract</p> <p>--</p> <p>-----</p>	20

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

30/04/2004

International application No.

PCT/SE 2004/000526

WO	9911667	A1	11/03/1999	AU	751784	B	29/08/2002
				AU	9438798	A	22/03/1999
				CA	2270176	A	11/03/1999
				EP	0944649	A	29/09/1999
				JP	2001505785	T	08/05/2001
				US	6362007	B	26/03/2002
				US	2002165355	A	07/11/2002

---